Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...
Whereas metastatic castrate-resistant prostate cancer used to have a poor prognosis, new agents are available and continuing to emerge with the potential to extend survival, but there is no ...